卡洛芬对结核分枝杆菌的多效杀菌机制及逆转耐药潜力
本研究旨在揭示非甾体抗炎药卡洛芬在分枝杆菌中的全细胞表型和转录组效应,采用整合分子与微生物学方法(包括刃天青微孔板试验、高通量斑点培养生长抑制试验、全细胞外排抑制、生物膜抑制和微阵列分析),并合成卡洛芬类似物评估其抗分枝杆菌活性。结果表明卡洛芬是杀菌剂,抑制分枝杆菌药物外排机制和生物膜生长,转录组分析提示其可能通过破坏膜电位靶向呼吸链,其多效作用可能解释实践中无法分离自发耐药突变株。该免疫调节药物及其化学类似物有潜力逆转结核抗菌药物耐药,为新型结核药物组合的临床试验提供快速路径。
要点
- 卡洛芬对复制态、非复制态及MDR临床分离株均有选择性抑制作用。
- 卡洛芬为杀菌剂,抑制分枝杆菌药物外排和生物膜生长。
- 卡洛芬可能通过破坏膜电位靶向呼吸链,多效作用或降低自发耐药风险。
核心结论
- 卡洛芬及其化学类似物有潜力逆转结核抗菌药物耐药,为新型结核药物组合的临床试验提供快速路径。
研究设计与样本
- 采用整合分子与微生物学方法:刃天青微孔板试验、高通量斑点培养生长抑制试验、全细胞外排抑制、生物膜抑制和微阵列分析,并合成卡洛芬类似物评估抗分枝杆菌活性。
主要发现
- 卡洛芬是杀菌剂,抑制分枝杆菌药物外排机制。
- 卡洛芬限制分枝杆菌生物膜生长。
- 转录组分析提示卡洛芬可能通过破坏膜电位靶向呼吸链。
- 卡洛芬抗结核作用的多效性可能解释实践中无法分离自发耐药突变株。
临床怎么用
- 卡洛芬作为免疫调节药物,其及类似物有潜力用于逆转结核抗菌药物耐药,可考虑推进新型结核药物组合的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rise of antimicrobial drug resistance in Mycobacterium tuberculosis coupled with the shortage of new antibiotics has elevated TB to a major global health priority. Repurposing drugs developed or used for other conditions has gained special attention in the current scenario of accelerated drug development for several global infectious diseases. In a similar effort, previous studies revealed that carprofen, a non-steroidal anti-inflammatory drug, selectively inhibited the growth of replicating, non-replicating and MDR clinical isolates of M. tuberculosis. OBJECTIVES: We aimed to reveal the whole-cell phenotypic and transcriptomic effects of carprofen in mycobacteria. METHODS: Integrative molecular and microbiological approaches such as resazurin microtitre plate assay, high-throughput spot-culture growth inhibition assay, whole-cell efflux inhibition, biofilm inhibition and microarray analyses were performed. Analogues of carprofen were also synthesized and assessed for their antimycobacterial activity. RESULTS: Carprofen was found to be a bactericidal drug that inhibited mycobacterial drug efflux mechanisms. It also restricted mycobacterial biofilm growth. Transcriptome profiling revealed that carprofen likely acts by targeting respiration through the disruption of membrane potential. The pleiotropic nature of carprofen's anti-TB action may explain why spontaneous drug-resistant mutants could not be isolated in practice. CONCLUSIONS: This immunomodulatory drug and its chemical analogues have the potential to reverse TB antimicrobial drug resistance, offering a swift path to clinical trials of novel TB drug combinations.
引用
- Maitra A, Evangelopoulos D, Chrzastek A, et al. Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis. J Antimicrob Chemother. 2020. PMID: 32790867. doi:10.1093/jac/dkaa307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。